Genetic Evidence Supporting Fibroblast Growth Factor 21 Signalling as a Pharmacological Target for Cardiometabolic Outcomes and Alzheimer’s Disease. This evidence concerns the gene FGF21 and early-onset autosomal dominant Alzheimer disease.